Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Simlukafusp alfa - Roche

Next Previous
Drug Profile

Simlukafusp alfa - Roche

Alternative Names: aFAP-IL2v; FAP-IL2v; FAP-IL2v FP; RG 7461; RO 6874281

Latest Information Update: 02 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche
  • Class Antibodies; Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
  • Mechanism of Action Fibroblast activation protein antagonists; Immunostimulants; Interleukin-2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Diffuse large B cell lymphoma; Malignant melanoma; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 21 Feb 2023 Hoffmann-La Roche terminates a phase II trial in Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in US, France, Germany, Israel, Russia, Switzerland, Turkey, Belgium, New Zealand, Poland, Singapore, South Korea, Spain, Taiwan, and the United Kingdom (NCT03386721) (EudraCT2017-003182-94)
  • 10 Nov 2022 Roche completes a phase I trial in in Solid tumors (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Denmark, France, Italy, Netherlands, Spain, United Kingdom, USA (IV) (NCT02627274)
  • 14 Jul 2022 Roche completes a phase I trial in Malignant melanoma (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in Australia, Belgium, Canada, France, Russia, Spain and USA (IV) (NCT03875079)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top